Core Viewpoint - The company has approved a plan to issue shares to specific targets for the year 2025, pending further approvals from shareholders, the Shenzhen Stock Exchange, and the China Securities Regulatory Commission [1] Group 1 - The total number of shares to be issued will not exceed 57.1188 million shares [1] - The total amount of funds to be raised is expected to be no more than 984 million yuan, with the net amount after deducting issuance costs to be fully allocated to specific projects [1] - The raised funds will be used for the cloud terminal computing center project, the intelligent upgrade of IoT terminal projects, and the research and development of thin terminal SoC chip technology [1]

Core Viewpoint - The company, China National Materials Technology (中材科技), plans to issue A-shares to specific investors to raise up to 448,114.92 million yuan for various projects and debt repayment [1][2]. Fundraising Details - The total investment for the projects includes: - 180,624.00 million yuan for the production of 35 million meters of low dielectric fiber cloth, with 166,200.00 million yuan from the raised funds - 175,089.00 million yuan for the production of 24 million meters of ultra-low loss low dielectric fiber cloth, with 147,500.00 million yuan from the raised funds - 82,014.92 million yuan for repaying state allocated funds - 52,400.00 million yuan for supplementing working capital - Total investment amounts to 490,127.92 million yuan, with 448,114.92 million yuan from the fundraising [2]. Issuance Structure - The shares will be issued as domestic listed ordinary shares (A-shares) with a par value of 1.00 yuan each, targeting up to 35 specific investors, including Zhonglian Investment, which plans to subscribe for 82,014.92 million yuan [3][4]. - The issuance will follow an inquiry-based pricing method, with the price set at no less than 80% of the average trading price over the previous 20 trading days [3]. Shareholding and Control - As of the announcement date, the total share capital of the company is 1,678,123,584 shares, and the maximum number of shares to be issued will not exceed 30% of the pre-issue total share capital, estimated at 503,437,075 shares [4]. - China National Materials Group, the actual controller of the company, will maintain its controlling stake post-issuance, ensuring no change in control [4].

Core Points - Jinpu Garden (301098.SZ) announced a plan to issue A-shares to specific investors, aiming to raise no more than 128.52 million yuan, which will be used to supplement working capital [1] - The shares will be issued at a price of 7.14 yuan per share, which is 80% of the average trading price over the last 20 trading days [1] - The issuance will involve a maximum of 18 million shares, representing 30% of the total share capital before the issuance [1] Shareholding Structure - As of the announcement date, the controlling shareholder Wang Yisen holds 38,220,000 shares, accounting for 21.18% of the total share capital before the issuance [2] - After the issuance, Wang Yisen's total shareholding will increase to 59,220,000 shares, representing 29.84% of the total share capital [2] - The issuance will not change the company's control structure, as Wang Yisen remains the controlling shareholder [2] Previous Fundraising Activities - Jinpu Garden was listed on the Shenzhen Stock Exchange on November 12, 2021, raising a total of 326 million yuan, with a net amount of 286 million yuan after expenses [3] - The company previously issued convertible bonds, raising 520,000 bonds at a face value of 100 yuan each, totaling 52 million yuan, with a net amount of 51.28 million yuan after fees [4] - The total amount raised from the two fundraising activities is 846 million yuan [5]

Core Viewpoint - The company, 罗欣药业, has announced a plan to issue A-shares to specific investors, aiming to raise up to 842.4 million RMB for various projects [1] Group 1: Fundraising Details - The issuance will target no more than 35 specific investors, including legal entities, individuals, or other legitimate investment organizations [1] - The total amount to be raised is capped at 842.4 million RMB, which includes the principal amount [1] Group 2: Use of Proceeds - The funds raised will be allocated to several key projects: - Innovative drug research and development projects - Expansion and technical upgrades of raw material drug production facilities - Supplementing working capital [1]

Core Viewpoint - 罗欣药业 plans to issue A-shares to specific investors, aiming to raise up to RMB 842.4 million for various projects [1] Group 1: Fundraising Details - The company intends to issue shares to no more than 35 qualified investors, including legal entities, individuals, or other legitimate investment organizations [1] - The total amount of funds to be raised is capped at RMB 842.4 million, which includes the principal amount [1] Group 2: Use of Proceeds - The raised funds will be allocated to the following projects: innovative drug research and development, expansion and technical upgrades of raw material drug production, and supplementing working capital [1]

Core Viewpoint - Zhongcai Technology (002080.SZ) plans to issue A-shares to specific investors, aiming to raise a total of no more than 4.481 billion yuan, with net proceeds allocated for various projects and debt repayment [1] Group 1: Fundraising Details - The issuance will involve no more than 35 specific investors, including Zhonglian Investment, which intends to subscribe for 820 million yuan of the shares [1] - The total amount to be raised is capped at 4.481 billion yuan, including the principal amount [1] Group 2: Use of Proceeds - The net proceeds from the fundraising, after deducting issuance costs, will be used for the following projects: - A project to produce 35 million meters of low dielectric fiber cloth annually - A project to produce 24 million meters of ultra-low loss low dielectric fiber cloth annually - Repayment of government allocated funds payable - Supplementing working capital [1]

Core Viewpoint - The company, Zhongcai Technology (002080.SZ), has announced a plan to issue A-shares to specific investors, aiming to raise a total of up to 4.481 billion yuan for various projects and working capital [1] Group 1: Fundraising Details - The issuance will target no more than 35 specific investors, including Zhonglian Investment, which plans to subscribe for 820 million yuan of the shares [1] - The total amount to be raised from this issuance is capped at 4.481 billion yuan, including the principal amount [1] Group 2: Use of Proceeds - The net proceeds from the fundraising, after deducting issuance costs, will be allocated to the following projects: - A project for an annual production capacity of 35 million meters of low dielectric fiber cloth - A project for an annual production capacity of 24 million meters of ultra-low loss low dielectric fiber cloth - Repayment of special government funding payables and supplementing working capital [1]

Core Viewpoint - The company, Zhongcai Technology, plans to raise no more than 4.481 billion yuan through a private placement to fund various projects and repay specific debts [1] Group 1: Fundraising Details - The company intends to raise funds for the annual production of 35 million meters of low dielectric fiber cloth [1] - Additionally, it aims to produce 24 million meters of ultra-low loss low dielectric fiber cloth [1] - The raised funds will also be used to repay national allocated funds and supplement working capital [1]

Core Viewpoint - The company plans to raise no more than 4.48 billion yuan through a private placement to fund various projects and repay debts [1] Group 1 - The company intends to use the raised funds for the annual production of 35 million meters of low dielectric fiber cloth [1] - The company also aims to produce 24 million meters of ultra-low loss low dielectric fiber cloth with the new funding [1] - Part of the funds will be allocated to repay special government funding payables and to supplement working capital [1]

Core Viewpoint - Beilu Pharmaceutical plans to raise up to 300 million yuan through a simplified procedure for a private placement of shares, with the funds allocated for specific projects and working capital [1][2]. Group 1: Fundraising Details - The total amount to be raised is capped at 30,000,000 yuan, which will be used for the "Luzhibao Chemical Drug Production Workshop and Intelligent Comprehensive Warehouse Project," a 100-ton iodinated contrast agent production line upgrade, a 50-ton iodinated alcohol raw material drug production line upgrade, and to supplement working capital [1]. - The issuance will be limited to no more than 35 specific investors, including qualified institutional investors and other eligible entities as per the regulations of the China Securities Regulatory Commission (CSRC) [2]. - The pricing benchmark for the shares will be set at no less than 80% of the average trading price over the 20 trading days prior to the pricing date [2]. Group 2: Issuance Conditions - The number of shares to be issued will be determined by dividing the total fundraising amount by the issuance price, with a maximum limit of 30% of the company's total share capital prior to the issuance [3]. - Shares acquired through this issuance will be subject to a six-month lock-up period post-issuance [3]. - The issuance is contingent upon approval from the Shenzhen Stock Exchange and registration consent from the CSRC [1][3]. Group 3: Previous Financing Activities - In 2020, Beilu Pharmaceutical issued convertible bonds with a total face value of up to 500 million yuan, with a net fundraising amount of approximately 489.22 million yuan after deducting related expenses [4]. - The bonds were issued at a face value of 100 yuan each, totaling 5 million bonds, and the issuance was approved by the CSRC [4].